IRLAB Therapeutics (IRLAB-A.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $60M

Market Cap: $11.5MFounded: 2010HQ: Gothenburg, Sweden

Sector Ranking#268 in Small Molecule Drugs #58 in Neuroscience & CNS

Overview

IRLAB Therapeutics is dedicated to transforming the lives of patients with Parkinson's disease through its innovative, data-driven discovery platform and focused clinical pipeline. The company's proprietary Integrative Screening Process (ISP) accelerates and de-risks drug discovery, having generated multiple clinical-stage candidates. With a Phase III-ready asset for dyskinesia and a strategic focus on the high-growth Parkinson's market, IRLAB is positioned to address significant unmet medical needs and create substantial value.

Parkinson's DiseaseCentral Nervous System (CNS) Disorders

Technology Platform

Integrative Screening Process (ISP): A proprietary systems pharmacology platform using machine learning to analyze a unique 25+ year database of CNS compound data to design and de-risk novel drug candidates.

Funding History

3

Total raised:$60M

IPO$30MUndisclosedJun 5, 2020

Series B$20MFlerie InvestJun 15, 2018

Series A$10MFlerie InvestJun 15, 2016

Opportunities

The global Parkinson's disease market is large and growing, with a severe lack of effective treatments for complications like dyskinesia, falls, and apathy.

IRLAB's targeted pipeline addresses these multi-billion dollar unmet needs, and its efficient ISP platform can continuously generate new candidates to capture further value.

Risk Factors

Primary risks include clinical trial failures, particularly in upcoming costly Phase III studies, and the need for significant dilutive financing to fund development.

Commercial success also depends on outperforming existing therapies and securing partnerships or market access.

Competitive Landscape

Competition in Parkinson's is segmented. For dyskinesia, IRLAB faces established products like Gocovri and Nuplazid. In areas like falls and apathy, competition is sparse, offering first-in-class potential. IRLAB's platform-driven efficiency is its key differentiator against traditional R&D models.